Diagnostics News and Research

RSS

Blood-based gene expression test more effective in ruling out obstructive CAD

A blood-based gene expression test was found to be more effective for ruling out obstructive coronary artery disease in stable symptomatic patients than myocardial perfusion imaging (MPI), a common test that uses a radioactive agent to evaluate the blood flow and function of the heart.

16 Nov 2011

TU Darmstadt chemists develop new method to diagnose Alzheimer's

Chemists at the Technische Universität Darmstadt have developed a new method for diagnosing Alzheimer's disease. The method involves making protein deposits on mucous nasal membranes that are detectable years before the disease erupts visible.

16 Nov 2011

Scil Proteins completes manufacturing agreement with Lundbeck

Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today the successful completion of a manufacturing agreement for Lundbeck, an international pharmaceutical company specializing in central nervous system disorders.

15 Nov 2011

Positive long-term data from Abbott's ABSORB drug eluting BVS trial on CAD

Abbott today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease.

15 Nov 2011

Positive data from MDxHealth's prostate cancer test study

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced data showing that a prototype of its Prostate ConfirmMDx test can help urologists distinguish patients who have a true negative biopsy from those who may have occult cancer undetected by prostate biopsy and histopathological review.

15 Nov 2011

Researchers in Philippines develop machine to quickly detect drug-resistant TB

In this post in the Global Post's "Global Pulse" blog, journalist John Donnelly reports on how a machine developed by researchers at the TB Laboratory at the Lung Center of the Philippines "that can detect multi-drug resistant tuberculosis (MDR-TB) in record time may revolutionize TB treatment."

15 Nov 2011

Corgenix first quarter total revenues increase 10.1% to $2.18 million

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, today filed its fiscal quarter Form 10-Q and reported financial results.

14 Nov 2011

Luminescent upconversion nanocrystals can detect cancer cells

Upconversion emission materials are ideal for bioimaging due to its effectiveness as contrast agents for the detection of cancer cells, more so when the background emission of non-cancerous tissues can be minimised. These materials could be used as biomarkers for luminescent labeling of cancerous cells. Opaque tissues can be turned into glassy, transparent substances by using these biomarkers which rely on near-infrared excitation.

14 Nov 2011

Leica Microsystems announces acquisition of Labindia's microscopy, histopathology business

Leica Microsystems, a world leading provider of microscopy systems and total histology solutions, today announced that it has acquired the microscopy and histopathology business of Labindia Instruments Pvt. Ltd., a leading solutions and service provider in India.

14 Nov 2011

GenMark Diagnostics third quarter revenues increase 90% to $1.3 million

GenMark Diagnostics, Inc. today reported financial results for the third quarter ended September 30, 2011.

10 Nov 2011

Transgenomic third quarter total revenue increases 87% to $8.3 million

Transgenomic, Inc. today reported financial results for the three and nine months ended September 30, 2011 and provided a business update.

10 Nov 2011

Salix to acquire Oceana Therapeutics

Oceana Therapeutics LLC, a privately owned global company focused on commercializing best-in-class specialty therapeutics, today announced it has entered into a definitive agreement for the sale of its operating subsidiary, Oceana Therapeutics, Inc. to Salix Pharmaceuticals, Ltd. of Raleigh, NC.

9 Nov 2011

Highmark now covers AlloMap for monitoring heart transplant rejection

XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive diagnostic tests to monitor immune-mediated conditions, today announced that Highmark Inc., an independent licensee of the Blue Cross Blue Shield Association, is now covering AlloMap for its beneficiaries.

9 Nov 2011

BioTime third quarter revenue increases 40% to $1.1 million

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.

9 Nov 2011

University of Houston to enhance cancer research facilities

Thanks to almost $1 million in new funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Houston (UH) will soon be enhancing its cancer research facilities.

9 Nov 2011

ScreenCell, Transgenomic sign collaboration and distribution agreement for CTC technology

Transgenomic, Inc. and ScreenCell, a privately-held company, today announced the signing of a perpetual, worldwide collaboration and distribution agreement for ScreenCell's Isolation Devices and Dilution Buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

9 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011

Medidata third quarter revenues increase 13% to $46.3 million

Medidata Solutions, a leading global provider of SaaS-based clinical technology solutions that enhance the efficiency of clinical development, today announced its financial results for the third quarter 2011, as well as provided financial guidance for the fourth quarter and full year 2011.

8 Nov 2011

NanoString closes $20M Series D round of equity financing

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it has closed $20 million in a Series D round of equity financing.

From NanoString Technologies 7 Nov 2011

Transgenomic and A. Menarini Diagnostics enter distribution agreement for mutation detection systems

Transgenomic, Inc. and A. Menarini Diagnostics today announced an exclusive distribution agreement for Transgenomic's SURVEYOR Scan and WAVE MCE (Micro-Capillary Electrophoresis) Mutation Detection system to its network of over 2,000 pathologists throughout Europe.

7 Nov 2011